0001599901-24-000077.txt : 20240605
0001599901-24-000077.hdr.sgml : 20240605
20240605174617
ACCESSION NUMBER: 0001599901-24-000077
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240604
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyce Sarah
CENTRAL INDEX KEY: 0001629383
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 241023202
MAIL ADDRESS:
STREET 1: C/O IONIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
wk-form4_1717623967.xml
FORM 4
X0508
4
2024-06-04
0
0001599901
Avidity Biosciences, Inc.
RNA
0001629383
Boyce Sarah
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
1
Common Stock
2024-06-04
4
M
0
28000
1.24
A
140117
D
Common Stock
2024-06-04
4
S
0
28000
27.4207
D
112117
D
Stock Option (Right to Buy)
1.24
2024-06-04
4
M
0
28000
0
D
2029-12-17
Common Stock
28000
817015
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.87. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
2024-06-05